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ABSTRACT
The human repair gene ERCC6-a presumed DNA (or
RNA) helicase-has recently been found to function
specifically in preferential nucleotide excision repair
(NER). This NER subpathway is primarily directed
towards repair of (the transcribed strand of) active
genes. Mutations in the ERCC6 gene are responsible
for the human hereditary repair disorder Cockayne's
syndrome complementation group B, the most
common form of the disease. In this report, the
genomic organization and expression of this gene are
described. It consists of at least 21 exons, together with
the promoter covering a region of 82-90 kb on the
genome. Postulated functional domains deduced from
the predicted amino acid sequence, including 7 distinct
helicase signatures, are-with one exception-encoded
on separate exons. Consensus splice donor and
acceptor sequences are present at all exon borders
with the exception of the unusual splice donor at the
end of exon VIl. The 'invariable' GT dinucleotide in the
consensus (C,A)AG/GTPuAGT is replaced by the
exceptional GC. Based on 42 GC splice donor
sequences identified by an extensive literature search
we found a statistically highly significant better 'overall'
match of the surrounding nucleotides to the consensus
sequence compared to normal GT-sites. This confirms
and extends the observation made recently by Jackson
(Nucl. Acids Res., 19, 3795 - 3798 (1991)) derived from
analysis of 26 cases. Analysis of ERCC6 cDNA clones
revealed the occurrence of alternative polyadenylation,
resulting in the (differential) expression of two mRNA
molecules (which are barely detectable on Northern
blots) of 5 and 7 kb in length.
INTRODUCTION
Nucleotide excision repair (NER) is one of the major DNA repair
systems functioning in mammalian cells (1). It is able to remove
a broad variety ofDNA lesions, such as UV-induced pyrimidine
dimers and (6-4) photoproducts, as well as bulky chemical
lesions and DNA cross links. After induction of DNA damage,
the NER machinery appears to be directed first primarily towards
the transcribed regions in the genome. This enables the cells to
rapidly resume the vital process of transcription, that otherwise
would remain blocked by lesions in the DNA template (2). This
preferential repair of active genes is even specific for the
transcribed strand (3). Removal of lesions from the non-
transcribed strand, as well as from inactive chromatin proceeds
more slowly and appears to be incomplete for several lesions
(4 for a recent review). In human cells, repair of the non-
transcribed strand is more rapid than that of inactive genes (5).
In the rare hereditary disorders xeroderma pigmentosum (XP)
and Cockayne's syndrome (CS), deficiencies in NER are thought
to underlie the clinical symptoms. XP patients are clinically
characterized by severe sun(UV)sensitivity of the skin,
pigmentation abnormalities, a highly elevated risk for developing
skin tumors, and often neurological degeneration (6). Cell fusion
experiments with cells from these patients have distinguished 7
NER-deficient complementation groups (cg; XP-A to XP-G) (7,
8). The biochemical basis for the XP NER-defect probably resides
in undefined early steps of the pathway preceding incision and
repair (9). For XP-C cells the defect appears to be specific for
repair of inactive chromatin; these cells have retained the ability
to remove damage from the transcribed strand of active genes
(10, 11, 12). CS patients have, in sharp contrast to XP, no
pigmentation abnormalities and no elevated risk for skin tumor
formation. They are clinically characterised by skeletal and retinal
abnormalities, growth retardation, progressive neurological
degeneration, and a sunsensitive skin (13, 14 for reviews). Like
XP, CS is heterogeneous: 2 cg have been identified (CS-A, -B)
(15, 16). The molecular defect in CS-A and -B was shown to
affect preferential repair of active genes only, whereas repair of
the inactive chromatin regions proceeds normally (17). A third
complementation group was defined (CS-C), containing one
patient that exhibited a combination of characteristics of XP and
CS. This patient is also classified as XP-B (16, 18). Several
patients exhibiting this combined XP/CS phenotype are reported;
one of these has been assigned to XP group D (8).
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Another class of mammalian NER-deficient mutants consists
of laboratory-induced, UV-sensitive, rodent (mainly chinese
hamster) mutant cell lines. Among these, at least 10 cg have been
defined (19, 20, 21, 22). A number of rodent mutants have been
succesfully used for isolation of human genes capable of
correcting the rodent repair deficiency (23 for a recent review).
Subsequent introduction of these genes into XP and CS cells has
demonstrated an overlap between the hamster and human cg:
rodent cg 2 and 3, corrected by ERCC2 and -3, are the rodent
equivalents ofXP-D and XP-B, respectively (24, 25). Recently,
we have isolated the human repair gene ERCC6 by virtue of its
ability to correct the UV-sensitivity of the Chinese hamster ovary
(CHO) mutant cell line UV61, cg 6 (26). The gene encodes a
protein of 1493 amino acids; the predicted amino acid sequence
suggests that the ERCC6 gene product is a nuclear DNA helicase.
Mutations in the ERCC6 gene appear to be responsible for the
repair deficiency of CS-B cells, implying that the ERCC6 gene
product is specifically involved in the process of preferential
repair (27). This paper describes the genomic architecture and
expression of the ERCC6 gene.
MATERIALS AND METHODS
General procedures
Purification of nucleic acids, restriction enzyme digests, gel
electrophoresis, DNA ligation, synthesis of radiolabeled probes
using random oligonucleotide primers, the polymerase chain
reaction (pcr), sequence analysis (dideoxy-mediated chain-
termination), and filter hybridization were performed according
to established procedures (28).
Construction of the cDNA plasmid
Construction of the (almost) full length ERCC6 cDNA was as
described (27). The cDNA insert was subcloned into both the
vector pTZ19R (Pharmacia) yielding pTZE6total, and the
mammalian expression vector pSLM, a derivative of pSVL
(Pharmacia; Van Duin, unpublished results). In the mammalian
expression vector the ERCC6 cDNA is under the control of the
SV40 late promoter, whereas in pTZE6total the cDNA is not
preceded by a eukaryotic promoter.
Cell culture, transfection, and selection
UV-sensitive CHO cell line UV61 and wt CHO cell line AA8
were grown in 1:1 FIO-Dulbecco minimal essential medium
supplemented with antibiotics and 8% fetal calf serum. The
ERCC6 cDNA construct pTZE6total (3 jig) was cotransfected
with 2 ,tg pSV2neo and 20 ,ug lambda phage 6B (see Fig. 1) to
UV61 cells. In order to release the lambda arms and plasmid
vector from the inserts prior to transfection, both pTZE6total
and lambda phage 6B were digested with Sal I; an enzyme which
does not cut within the insert. Transfection and selection were
performed as described before (27).
Identification of intron-exon borders
All genomic fragments hybridizing to the ERCC6 cDNA were
subcloned in pTZ19R (Pharmacia) or pBluescript II KS
(Stratagene), and sequenced with ERCC6-specific primers. All
sequence reactions were performed on double-stranded templates
by the dideoxy chain termination method, using T7 DNA
polymerase (Pharmacia). Intron length was determined either by
analysis or by pcr with exon-specific primers on subcloned
genomic fragments.
Northern blot analysis
RNA samples were separated on an agarose gel and transfered
to a nylon membrane (Zeta probe from Bio-Rad) as described
by Fourney et al. (29). The filters were hybridized at 65°C, in
3 x SSC, 10 x Denhardt's reagent, 0.1% SDS, 90 Ag/ml dextran
sulfate, and 50 ,g/ml denatured salm sperm DNA. Filters were
washed 2 times (10 min.) in 3xSSC, 0.1% SDS and once (10
min.) in lxSSC, 0.1% SDS, at 650C.
Synthesis of strand-specific probes
Strand-specific probes were synthesized according to the method
described by Espelund et al. (30), with several modifications.
The template was generated by pcr, with one normal and one
biotinylated primer. The biotinylated product was then bound to
streptavidin-coated magnetic beads (Dynabeads M-280, Dynal)
through a 30 min. incubation at 37°C in 5 xSSPE (20xSSPE:
3.6M NaCl, 200mM NaH2PO4 pH7.4, 20mM EDTA pH7.4).
The beads were washed 4 x with a solution containing 0.17%
(w/v) Triton X-100, 100 mM NaCl, 10 mM Tris.HCl pH7.5,
and 1 mM EDTA; subsequently the non-biotinylated strand was
removed by 2 cycles (7 min. each) of denaturation in 125 mM
NaOH, 100 mM NaCl. After washing twice with 100 mM
Tris.HCl pH7.6, 150 mM NaCl, the biotinylated strand is
radioactively labeled via primer extension. The beads were
washed 3 x, and the DNA was denatured by two incubations (7
min. each) in 125 mM NaOH, 100 mM NaCl. The supernatant
was neutralized with an equal volume of IM Tris.HCl (pH7.5),
and used in hybridizations.
RESULTS
Architecture of the ERCC6 gene
ERCC6 promoter region. The ERCC6 gene was isolated from
a lambda EMBL3 library originating from a repair-proficient
secondary UV61 transformant. The genomic region coinherited
by independent, repair-proficient primary and secondary UV61
transformants, as judged by Southern blot analysis, was
approximately 100 kb, and consequently separated over several
lambda clones (26). A physical map of this region is shown in
Fig. 1. The size of the ERCC6 locus was determined by
hybridization of an (almost) full length, functional cDNA of 4.7
kb, encoding at least the total open reading frame and the 3' end
(of the shortest mRNA, see below), to the different lambda
clones. The cDNA, previously localized on chromosome
IOqi 1-21 (31), was shown to encompass 82 kb at the genome
level (Fig. 1) and to reside on a 430 kb Not I fragment (data
not shown). One of the Not I sites is part of a CpG-island present
in the 5' region of the ERCC6 gene (Fig. 1). To pinpoint the
region containing the promoter and the 5' untranslated end of
the mRNA (part of which might be lacking in the cDNA), a
promoterless cDNA construct (pTZE6total, see Materials and
Methods) was cotransfected with lambda clone 6B, containing
the first 4 exons present in the cDNA, and approximately 8 kb
more upstream sequences (Fig. 1). To be expressed, the
promoterless cDNA should recombine within the cell with the
cotransfected lambda phage, thus producing a 'mini gene'. After
transfection of the two DNAs together UV-resistant clones were
restriction enzyme digestions and subsequent Southern blot obtained, with an efficiency that was = 1Ox lower than after
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Figure 1. Genomic organization of ERCC6. A physical map of the ERCC6 locus is shown. Exons (I to XXI) are indicated by boxes on the bar underneath the
map. cDNAs from the two encoded, differentially poly-adenylated mRNAs are shown; white and hatched areas represent untranslated regions, the black area represents
the ORF. Exon borders in the cDNA are indicated by vertical lines on top of the shortest cDNA. Phage 6B: a X-phage containing the promoter region of the ERCC6
gene. The * indicates a CpG-island encompassing a Bss HI, Not I, and a Sac II restriction enzyme site located just 3' of exon 1. Other symbols: S, Sal I; B, Bam
HI; short bars in the map represent Eco RI restriction sites.
transfection of a eukaryotic expression vector carrying the ERCC6
cDNA behind the SV40 late promoter. The UV-sensitivity was
corrected to a level within wt range (Fig. 2), as determined by
survival experiments with pooled clones. To rule out the
possibility that the UV-resistant transformants obtained in the
cotransfection experiments were caused by fortuitous integration
behind an endogenous promoter, instead of reconstitution of a
functional gene by recombination between the 5' ERCC6 gene
part with the rest of the cDNA, we also transfected the cDNA
without a functional promoter at its 5' end. In this experiment,
in which the cDNA was placed in the inverted orientation in
vector pSLM, no UV-resistant clones were obtained. These
findings strongly suggest that a functional gene has indeed been
generated via homologous recombination (between the lambda
and cDNA clones) within the cell. The promoter should then be
situated within the 8 kb genomic region 5' of the first exon
present in the cDNA clone. The ERCC6 locus thus covers a
region of 82-90 kb.
Intron exon structure. Appropriate fragments were subcloned into
plasmid vectors in order to determine intron-exon borders.
Sequence analysis demonstrated the ERCC6 cDNA to be
dispersed over 21 exons (Fig. 1). The CpG-island present in the
5' region of the ERCC6 gene is situated within the first intron
of ERCC6 (Fig. 1). The first exon present in the cDNA does
not contain any coding information, analogous to the first exon
in another repair gene, ERCC1 (32). Since we have not
determined the transcriptional start site, we cannot exclude the
presence of an additional exon more 5' on the genome, which
is absent in the cDNA. The presence of a CpG-island in the first
intron, however, argues against the existence of an additional
5' exon located far upstream. The tentatively identified functional
domains are-with the exception of helicase signature VI-
encoded by separate exons (Fig. 3 and 4).
As shown in Fig. 3, all sequences around intron-exon and
exon-intron borders are consistent with the consensus splice
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Figure 2. Correction of the UV-sensitivity of mutant UV61 by the ERCC6 gene.
UV survival curves of wild type CHO cell line AA8 (c *), mutant UV61
(0.. -.. 0), and UV61 cells cotransformed with X-phage 6B (see Fig. 1) and a
promoterless ERCC6 cDNA (A...A).
acceptor and donor signals (33), with the exception of the splice
donor of the intron VII. The canonical GT dinucleotide at the
beginning of the intron is replaced by GC (see below). In all
introns, the weakly defined branchpoint sequence
(PyNPyTPuAPy) could be tentatively identified at the appropriate
distance (10-50 nt) from the splice acceptor site (underlined in
Fig. 3) (33, 34). One alternatively spliced cDNA molecule has
been isolated, in which exon VII was found to be skipped. The
sizes of internal exons range from 79 to 745 nt. Three of the
internal exons (exon II, V, and XVIII) have an exceptional size:
ERCC-6
N
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TACAATGAATCCTATATAACGAAAA 166
GGCTTATAAATTTTTTTCCTTTTAG GTAGTC
TATAAAAATGTTATCAGAGTGCAAA 502
ATAGACAATTTATCTTATTTTTCAG GTCATG
CAATAAATCACTTCATTGCTGTTTT 623
CTGTCTTCTATATTTACCATTCAAG GAACAA
CCCTCGGAAAGTTTCATGCTAGTGG 1732
CAAAGCATTGCTATTGTTCTTTCAG AGCCGG
TCTGTCTTGTGATCAAAATAATGGA 1477
AATGTGATTTTTATTTTCATGGTAG GAGATG
TATCCACCATTTGCCATTTTCTCTT 1606
TTCTTGTTGGTGTTTGTTGTCATAG GTACCA
TCTTTCATGGTT 1765
GTTTTCTTCTTGCGTTTGGATGCAG GTTTGA
GGTGTCACTTCTTATTTAAAACTGA 1901
CTTTACCATTTTATTGTGGTCTCAG GAGAAA
GATTGCTAAAAGGTAAATTTAATAA 2072
AAAGGTGCTTCCTTTCCTCAAATAG TTTCGC
TTCCTTAAACATATATAGTAAT 2249
GTTCCCTTCTCTGCTCTTATTAAAG GTCAAA
GTTAATTTTTTTTTTGAAATTATAG 2366
TTTCCTTGTTTTTCCCGGTTCGTAG GTCTTA
TTACTTTACATGGGGTCATCTGAGT 2462
GTACATGTACTCTTTCTTACGACAG ATTTTC
CTGGGAATGTGTATTTGCTTTGCAA 2678
ACTCCTATCCCCCACCTCCAAACAG ATGCTG
TGTAACTGGTCTTAAGTGTGTGTGC
TCAGTGTTGTGTGTCTTACCTCTAG
GTCATTGGGAAGGATTCTCGTTG
AGAGGTCTCTCTCTCTCTGTTGCAG
TAGGTAGAGCTACACATTGTTTTAT
ACCAGCTTATCTTTTATTTTTTTAG
TTGCACAAGATGATACAATATAGTA
TTAGTGGTGTTTTTCCTCTTTACAG
TTTCTTGCATACAGAGTGAAATATC
ACTTTGCTATTTCTTTTCTTGCTAG
AAGTCTCAAAAGCAAACATTTAATC
TACTGTGATGCTTTTCCTTTTTTAG
GGCATAAACTAGAAATTAAATATAT
2789
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XIV (111)
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Figure 3. Structural organization of the ERCC6 gene. The nucleotide sequence of each intron-exon junction is shown, with the exception of the splice donor of
exon I. The vertical lines represent intron-exon borders. The splice donor of exon VII has a GC dinucleotide (indicated in bold) at the position of the canonical
GT. All other acceptor and donor sites are in reasonable accordance with the consensus sequence (Py)nNCAG/G and (C,A)AG/GTPuAGT (33). The nucleotides
at the borders of each exon are numbered as reported previously (27). The size of introns and exons are given between parenthesis (in bp, if not indicated otherwise).
The postulated functional domains (27) encoded by the different exons are indicated: acidic, stretch of acidic aa; NLS/CKII, putative nuclear location signal followed
by a postulated casein kinase II phosphorylation site; heli I to VI, helicase domains I to VI; NTB, putative nucleotide binding fold.
436, 745 and 708 nt, respectively; the average exon length for libraries were screened for the presence of clones with extra
vertebrate internal exons being 137 nt (35). Intron lengths range sequences not found in the 4.7 kb cDNA. One of the isolated
from 85 to 19,000 nt; the average size of vertebrate introns being (partial) cDNAs had a 3' untranslated region extending 2 kb more
1,127 nt (35). 3' as the mentioned 4.7 kb construct. It contained a poly(A)tail,
preceded by the common polyadenylation signal AATAAA (36,
ERCC6 gene expression and alternative polyadenylation 37). The total length of the isolated cDNA then becomes i 6.7
Northern blot analysis of human poly(A)+ RNA demonstrated kb, probably reflecting the longest mRNA. Sequence analysis
the presence of two ERCC6 transcripts of approximately 5 and and restriction enzyme digests showed the 3' untranslated region
7 kb in length, both expressed at a very low level (Fig. 5). To to be colinear with the genome. This suggests the 2 mRNA
examine the structure of the long ERCC6 mRNA, various cDNA products to be the result of alternative polyadenylation (Fig. 1).
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Figure 4. Schematic depiction of the postulated functional domains as encoded by different exons. The shaded area represents the ORF; encoded domains are indicated
above the exons. Intron length is given in kb. Symbols: A, acidic amino acid stretch; S, putative nuclear location signal followed by a postulated casein kinase
II phosphorylation site; N, putative nucleotide binding fold. The interrupted box added to exon XXI indicates the 3' end of the longest ERCC6 mRNA, produced
by alternative polyadenylation.
Analysis of mouse tissues revealed the presence of elevated
(though still very low) levels ofERCC6mRNA in brain and testis;
in most other tissues transcription was below detection level
(Fig. 5). Also in mouse two transcripts are identified, suggesting
that the alternative polyadenylation is conserved. Remarkably,
the larger transcript is the most abundant in mouse brain, whereas
in testis the smaller mRNA is the more frequently occurring one
(Fig. 5).
In human RNA, a third transcript of 3.5 kb is detected, with
probes in the 5' 1.7 kb of the gene. A probe from nt 1662 to
3746 did not detect this short transcript. Both a probe covering
the first 350 bp of the cDNA (exon I and part of exon H) and
one spanning nt 1020 to 1667 (part of exon V, exon VI and 60
nt of exon VII) recognize this short transcript, suggesting that
at least sequences from exon I or II as well as exon V or VI
(and maybe the 60 nt of exon VII) should be present. The
transcript is detected in both total and poly A+ RNA.
Hybridizations with strand-specific probes, as shown in Fig. 5,
have excluded the possibility of an overlapping antisense gene:
the transcript appears to be produced from the same strand as
the two longer ERCC6 mRNAs. Since we have been unable to
identify ERCC6 transcripts in mouse tissues with a 5' probe, it
is unclear whether the 3.5 kb transcript is conserved through
evolution.
DISCUSSION
The ERCC6 gene product, which is predicted to be a nuclear
DNA helicase, has recently been shown to be involved in the
human DNA repair disorder Cockayne's syndrome (27). In this
paper, the expression and structural organization of the ERCC6
gene are reported.
Two lowly expressed ERCC6 mRNA molecules of 5 and 7
kb have been identified by Northern blot analysis of human
poly(A)+ RNA (Fig. 5). Two types of cDNAs have been
isolated, varying in their 3' end by differential polyadenylation.
The second polyadenylation site, accompanied by the common
polyadenylation signal AATAAA, is present 2 kb downstream
of the first one that contains the less preferred signal ATTAAA
(36, 37). Alternative polyadenylation occurs in many genes,
including another human NER gene ERCCI (32). It is unclear
though, whether this has any regulatory function. In this respect,
it is interesting to note that often the alternative polyadenylation
is evolutionarily conserved, as it is-presumably-for ERCC6.
We noted differential expression of the two transcripts in mouse
brain and testis (Fig. 5). It is unknown whether the elevated
expression of the longest ERCC6 mRNA in brain is related to
the (severe) progressive neurological degeneration in CS patients.
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Figure 5. Expression of the ERCC6 gene. A: Northern blot analysis of 5 jig
poly(A)+ mRNA from HeLa cells, hybridized with a 32P-labeled ERCC6 cDNA
fragment extending from nt 1662-3746 (middle probe). B: Northern blot analysis
of 5 ltg poly(A)+ mRNA from HeLa cells and STI, a secondary repair proficient
transfornant of UV61, containing the human ERCC6 gene (26). The blot is
hybridized with a strand-specific probe (32P-labeled transcribed strand, TS)
spanning nt 16 to 1667 from the ERCC6 cDNA. A radioactively labeled non-
transcribed strand did not recognize any transcript (result not shown). C: Northern
blot analysis of 20 iLg of total RNA from different mouse tissues. The probe used
is similar to that in A.
Also the function of the (human) 3.5 kb transcript encompassing
only the 5' region of the ERCC6 cDNA is unresolved.
Hybridization with strand-specific probes ruled out the possibility
of an overlapping antisense gene. An overlapping gene in sense
direction seems unlikely, since it should then have (parts) of at
least 2 exons (exons I or II and V, VI or VII) in common with
the ERCC6 gene. A third possibility is that the 3.5 kb transcript
is the result of a (strong) transcriptional stop due to the presence
of an attenuation site. The attenuation site should then be within
or 3' of exon V, which is approximately 15 kb (or more) from
the transcriptional start site. Normally, attenuation takes place
within a few hundred bp from the transcription initiation site,
although there is one example of a termination site = 2 kb from
the start (c-nyb) (38). If, for the ERCC6 gene, the stop site is
3' of exon V, it could be within the 19 kb long intron V. Cross-
hybridization of unique human sequences from this intron to
rodent DNA suggested the presence of 2 conserved regions within
intron XIX (unpublished observations). It is possible that a second
gene is located within this large intron, with transcription
termination sequences that can be recognized by RNA polymerase
complexes transcribing the ERCC6 gene. Splicing of this
prematurely terminated transcript might result in the observed
3.5 kb mRNA. A more conclusive statement concerning the role
of this short (truncated) ERCC6 transcript should, however, await
further research, particularly by the isolation of corresponding
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Table I. Summary of GC-splice donor sequences
GENE SEQUENCE REFERENCE
EXON INTRON
Human cytochrome P-450 CACTAAG GCAAGCCCACA (43 and references therein)
Hamter &A-crystallin CATCAAG GCAAGTTACAT (43 and references therein)
Mouse A-crystattin CGTCAAG GCAAGTTACAT (43 and references therein)
Mote rat aA-crystattin CATCAAG GCAAGTTTCGT (43 and references therein)
Chicken aD-gtobin TTTCAAG GCAAGCAAAGG (43 and references therein)
Duck D-gtobin CTTCAG GCAAGCGGGGA (43 and references therein)
Chicken myosin heavy chain GCTGCAG GCAAGTGTCTG (43 and references therein)
Rat heme oxygenase TCGACAG GCAAGCGACTA (43 and references therein)
Soybean nodutin-24 AAAG_GG GCAAGTTMTT (43 and references therein)
Human factor XII AGGACG GCGAGTACCCG (43 and references therein)
Pig growth hormone GCTGCAG GCAAGTGCCCC (43 and references therein)
Human acetytcholine receptor CCGCAAG GCAAGGACCCT (43 and references therein)
Rat pyruvate kinase CACCCAG GCATGTGCTAT (45)
Human superoxide dismutase-1 GCAG AGCMGGGCTGG (43 and references therein)
Mouse superoxide dismutase-1 GCAG;aG GCAAGGCCCGG (43 and references therein)
Human prothrombin TGTGCTG GCAAGTCTGTG (43 and references therein)
Human factor VII GCTGCAG GCGGGGTCGCT (43 and references therein)
Human erythrocyte e-spectrin CATTCAG GCAAGTTCAA (46)
Rat D2a receptor AATACAG GCAAGTCTGGC (47)
Earthworm hemogLobin chain c TCACCM GCAAGTCTCCC (43 and references therein)
Minute virus of mice TTTACAG GCCTGAAATC (48)
Human e-gtucosidase CACCAAG GCAAGA (49)
Bovine aspartyt protease TGGCGAG GCAAGTCCAG (43 and references therein)
Mouse APRT ATCGCAG GCGAGTGGCCT (43 and references therein)
Hamster APRT ATCGCAG GCGAGTGGCCA (43 and references therein)
Humn APRT ATCGCAG GCGAGTGCCAG (43 and references therein)
Neurospora qa repressor CCTCTAG GCACGTCTGTA (43 and references therein)
Human argininosuccinate Lyase GCTGCAG GCAAGACATCA (50)
Mouse TRP-1 GTGGAAG GCAAGTAA (43 and references therein)
Murine fifth comptement (CS) ACGGGCT GCAAGTGGT (51)
Human ptatetet GP lIb (exon V) CACTCAG GCGAGTAGGGA (52)
Humauptatetet GP Ib (exon VIII) ACTACA GCAGAAATCC (52)
Human keratin 18 CGAAGAG GCAAGCAGGGG (43 and references therein)
House RNA polymerase (exon VII) CTATAAG GCATGTAAATA (43 and references therein)
Mouse RHA potymerase (exon XIII) CTCCCA GCAAGATGCTT (43 and references therein)
E.typhina TUB-B CAACGAG GCAAGTCTTCA (53)
Rat ESP-1 CTATCAG GCAAGAATGCT (54)
HSV-1 LAT CAAGAAG GCATGTGTCCC (55)
Human C3 TACCCAG GCAAGT (56)
Human DNA tigase I ACGCAG GCAAGT (57)
Human ERCC3 TATTAAG GCAAGTGACAG (40)
Human ERCC6 ATTACAG GCAAGTGCTCC (This paper)
Sequene complementary to Ul snRNA CAG GTAAGT (58)
cDNAs. So far, no such cDNAs have been isolated, despite the
screening of several cDNA libraries.
The ERCC6 locus is 82-90 kb in length, and harbors at least
21 exons. The presence of a CpG-island within intron I (Fig. 1)
suggests that there is no unidentified exon more 5' (containing
extra 5' untranslated sequences not present in the cDNA),
although we cannot completely exclude this possibility. It is
interesting to note iat also ERCC2 and ERCC3 have CpG-islands
witiin the first intron (39, 40). The putatively identified functional
domains in the ERCC6 cDNA sequence are-with one
exception-dispersed over separate exons. It has been proposed
that modem eukaryotic genes may have been assembled from
a limited number of ancestral exons encoding separate functional
domains (41). Within ERCC6, only helicase domain VI is split
by intron XV (see Fig. 3 and 4). Interruption of helicase domains
by introns has been noted before: yeast RNA helicase p68
contains one intron in domain V (42), which is positionally
conserved (between human, Saccharomyces cerevisiae, and
Schizosaccharomycespombe); within the ERCC3 gene (encoding
a putative DNA helicase) both domain I and V are interrupted
(40).
In one of the isolated ERCC6 cDNAs exon vm was found
to be skipped. Although we cannot completely exclude the
possibility that a mRNA molecule without exon VII has any
functional potential, it seems unlikely. The exon skipping results
Table H. Nucleotide percentages at GC-type compared to GT-type splice donors
Consensus
-l -2 -3 - 2 4 5
GTsplice' C/A A G G T AJG A G T
G 1c8 1o2 IA-I.OI.535 1 1 18
A 32 9- . = 7 lff
T 13 is 7 = 100 3 9 a
C E 13 5 _ _ 3 9 6 1
GC splce' C A G |G |C| A |A |G |T|
G9.5 2.4 1043|2.49.5|
A 38.1 i-0-0 2.4 == 143
T 2.4 2.4 2.4 .. 9.5 . _
C 4._ = 100 2.4 2.4 = 3
Significance of increased complementutity to U1I snRNA in GC splice donor ses (shded box")
p-values ! <0°jl <0.001 <0.001 <0.05 l00coo 0l1ci
a Data taken from reference (33).
Percentages are based on 3724 different slice donors.
b Data from this work and reference (43).
Percentages are based on 42 different splice donors.
c ns = not significantly different.
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in a frameshift; consequently, the mRNA only encodes a very
short protein. Presumably, this unconventionally spliced mRNA
is the result of an erroneous splice event, rather than the product
of a mechanism that creates an alternative, functional ERCC6
protein.
All splice sites, with the exception of the splice donor at the
3' end of exon VII, are in reasonable accordance with the
consensus sequences (Py)nCAG/G and (C,A)AG/GTPuAGT for
donor and acceptor, respectively (33). In the splice donor of
intron VII, the 'invariable' GT dinucleotide is replaced by GC.
'GC' instead of 'GT' splice donors are very rare. Recently,
Jackson (43) compared 26 'GC' splice donors from the literature,
and noted that as a group they have a better 'overall' match to
the (C/A)AG/GTAAGT consensus than the regular 'GT' donors.
To assess the validity of this finding and to make conclusions
statistically more significant, we have screened various data bases
for additional 'GC' splice donors, and extended the list to a total
of 42 (Table I). The comparison presented in Table II clearly
confirms and strengthens the observation made by Jackson: 'GC'
splice sequences display as a whole at all (remaining) positions
a substantially higher level of complementarity to the Ul snRNA
than the group of 'GT' donors. Particularly the G residue at
position +5 seems invariant, whereas the 'G' at -1 is almost
invariant. Most sites have 6-8 bases matching Ul snRNA (6
sites have 8 matches, 21 sites have 7 matches, 12 sites have 6
matches, the remaining 3 sites only have 5 bases matching to
U1 snRNA). Apparently, the mismatch in base pairing with Ul
snRNA caused by the GT to GC alteration needs to be
compensated by a better match of the rest of the sequence, in
order to permit the assembly of a functional spliceosome.
Three of the internal ERCC6 exons (exons without either a
cap site or a polyadenylation signal) are exceptionally large: 436,
708, and 745 nt (exons II, XVII, and V respectively). Out of
1305 internal vertebrate exons examined by Hawkins, only 7
exceed 550 nt; the average length being 137 nt (35). A
conceivable explanation for the scarcity of large internal exons,
as proposed by Robberson and colleagues (44) is based on the
idea that, in order to stably form a spliceosome, factors bound
at the 5' and 3' border of an exon need to 'communicate'. The
interaction between the different factors might become less stable
if the exon length exceeds a certain limit. In vitro splicing
experiments demonstrated splicing of an intron followed by a
large exon (> 300 nt) to be less efficient than splicing of the same
intron preceding a small exon (< 300 nt) (44). Whether this is
true in vivo too, is unknown. If so, it might (partly) explain the
low expression level of the ERCC6 gene.
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